Objective: To evaluate the diagnostic properties of multiparametric magnetic resonance imaging in the detection, localization and characterization of prostate cancer using three-dimensional transperineal template mapping biopsy histopathology as the comparator. Methods: A retrospective analysis of patients undergoing prostate multiparametric magnetic resonance imaging followed by three-dimensional transperineal template mapping biopsy was carried out. For imaging and pathology data, the prostate was divided in octants with the urethra being the midline. The index test properties were calculated using the biopsy histopathology as the reference test with the following endpoints: any cancer, any Gleason ≥7, any Gleason ≥7 or cancer length of ≥4 mm and any Gleason ≥7 or 6 mm in any given core. The latter two definitions correspond to 0.2 and 0.5 mL of cancer volume, respectively. Diagnostic properties including sensitivity, specificity, positive and negative predictive values were calculated. Results: A total of 50 patients were included in the study. A median of 55 (interquartile range 42-63) biopsy cores were obtained per patient. Of 400 prostate octants evaluated, 28.5% had prostate cancer on mapping biopsy, whereas 23% of octants were considered suspicious for cancer on imaging. Multiparametric magnetic resonance imaging negative predictive values for Gleason ≥7 and clinically significant cancers were 84-100%. Similarly, specificity ranged between 79% and 85%. Sensitivity and positive predictive value remained moderate for all the reference test definitions. Conclusions: Multiparametric magnetic resonance imaging is a useful minimally-invasive tool for detection, localization and characterization of prostate cancer. This imaging modality has high negative predictive value and specificity, and therefore it could be used to reliably rule out clinically significant cancer, obviating the multicore mapping biopsy.
Introduction
PCa is the most common malignancy in men, with an estimated 180 890 new cases in 2016. 1 However, mortality from this disease is disproportionately low compared with its incidence. 1 The randomized controlled Prostate Cancer Intervention versus Observation Trial showed that overtreatment of PCa remains a significant concern. 2 Currently, PCa diagnosis still relies on TRUS biopsy, which, because of its sampling nature, can either miss clinically significant cancers or detect those that are not. In recent years, mpMRI consisting of several magnetic resonance functional sequences has been proposed as a tool for detection, localization and staging of PCa. [3] [4] [5] It was suggested that mpMRI might be a reliable method to rule out clinically significant cancer when compared with wholemounted radical prostatectomy specimens, 6, 7 and could aid in the selection of candidates for active surveillance 8, 9 and focal therapy. Three-dimensional TTMB offers the most comprehensive pathological sampling of the prostate in situ with acceptable morbidity. [10] [11] [12] Thus, as a reference test for evaluating diagnostic properties of mpMRI, TTMB largely avoids the sampling bias of office-based TRUS biopsy, as well as verification bias of radical prostatectomy specimens. When assessing for clinically significant cancers, it is not clear whether mpMRI alone can supplant the detailed histological analysis of TTMB, particularly regarding patient selection for focal therapy, whereby this issue still remains unresolved. 13, 14 In the present study, we sought to evaluate the diagnostic properties of mpMRI compared with TTMB to assess the ability of mpMRI to detect, localize and characterize (grade, clinical significance) PCa in a minimally-invasive fashion.
Methods
After approval from the institutional review board, a retrospective chart review was carried out to identify consecutive patients who underwent mpMRI followed by 3-D TTMB at Duke Cancer Institute, Durham, North Carolina, USA, over a 3-year period beginning in 2011. The indication for TTMB was either evaluation of elevated PSA with prior negative conventional office-based TRUS biopsies or restaging of potential candidates for active surveillance or focal therapy. Patients with prior prostate cancer treatment were excluded. Similarly, mpMRI studies not carried out at our institution were not included in the present analyses in order to minimize variance as a result of differences in image acquisition technique.
mpMRI technique and evaluation
MRI were obtained on one of two 3.0 Tesla clinical MR scanners (Signa HDx; GE Healthcare, Wausau, WI, USA; and Skyra; Siemens Healthcare, Erlangen, Germany) using a combination of multichannel phased array body coils, as well as a single-channel endorectal coil (Medrad, Warrendale, PA, USA). T2-weighted fast-spin echo images were acquired in multiple planes (axial, coronal and sagittal) using a small field-of-view technique and section thickness of 3 mm for anatomical images. Functional imaging sequences, including diffusion-weighted imaging and dynamic contrast-enhanced MRI were also included as part of the standard mpMRI protocol at our institution. Diffusion-weighted imaging was carried out with two b-values of 0 and 800 to facilitate creation of automated diffusion coefficient maps. Dynamic contrastenhanced MRI was acquired at a temporal resolution of 5-6 s for 5-6 min after the intravenous injection of a weightbased dose of gadopentetate dimeglumine (Magnevist; Bayer Pharma AG, Berlin, Germany). All image interpretation was carried out on a picture archiving and communication system (Centricity; GE Healthcare) by a single board-certified, fellowship-trained radiologist with 5 years of experience in interpretation of mpMRI (RTG).
TTMB technique
Our TTMB technique was previously described. 10 Briefly, TTMB was carried out under general anesthesia, in the dorsal lithotomy position. After prostate measurements were taken with TRUS, 26 defined regions of the prostate corresponding to anterior/posterior, left/right and distal, and proximal sectors were sampled using a 5-mm grid (Fig. 1a) . Depending on prostate size/volume, between one and five specimens were harvested from each zone, placed in a formalin-filled specimen cup and submitted for pathological analyses. Each biopsy was verified under transverse and sagittal imaging. All biopsy specimens were evaluated by uropathologists at our institution. A 3-D pathological map of the prostate was detailed based on cancer location and core length.
Data collection
We collected demographic, clinical, imaging and pathological data. For imaging and pathological data, the prostate was divided into eight segments corresponding to left/right, apex (distal)/base (proximal) and anterior/posterior boundaries with the urethra being the midline (Fig. 1b , similar to a previously reported schema 15 ). Pathological data recorded included the number of cores, pathological diagnosis, Gleason score and maximum length of cancer in any core for every one of the eight segments. Similarly, mpMRI images were interpreted in a blinded fashion, and suspicion of cancer was quantified on a scale of 1-5, with 1 being highly unlikely to represent significant cancer and 5 being highly likely to represent significant cancer. At the time of the study (2011-2014), PI-RADS v.2 was unavailable. The Likert score was used in the present study, since it has been shown to be an acceptable model to quantify cancer suspicion. 16, 17 Also, data show that it performs as well as PI-RADS v.1 for disease localization, except in the transition zone, in which the Likert score performs better. 18 mpMRI scores of 3-5 were considered positive. In addition, a subset analysis of scores 3 and 4-5 was carried out.
Statistical analysis
mpMRI results (index test) were compared with the TTMB histopathology findings that were considered the reference test for the purposes of the present study using four different pathological end-points; namely, any cancer, any Gleason 7 cancer and two definitions of likely significant cancer (any Gleason ≥7 or cancer length of ≥4 mm or 6 mm in any given core). The first definition identifies cancers of 0.2 mL and above, whereas the second sets the threshold to 0.5 mL of cancer volume as described by Hu et al. 11 We assessed the mpMRI scores against these four end-points. mpMRI diagnostic properties (sensitivity, specificity, PPV and NPV with 95% confidence intervals) were calculated for the apex, base, anterior and posterior prostate, as well as using all eight segments. Statistical analyses were carried out using the R v.2.15 software (the R Foundation for Statistical Computing, Vienna, Austria) with "Hmisc" and "epiR" libraries. All data are presented as number (percentage) or median (interquartile range). All diagnostic properties are presented with 95% confidence intervals.
Results
A total of 50 patients were included in this detailed pathological mapping and radiological correlative study. Patient characteristics are summarized in Table 1 . Out of 400 prostate segments sampled, 114 (28.5%) had cancer on TTMB, including 55 (13.8%) cancers with Gleason 7 or higher, and 70 (17.5%) and 61 (15.3%) segments harbored clinically significant PCa using the two definitions (Gleason 7 or volume of 0.2 mL and Gleason 7 or volume 0.5 mL or more), respectively. Imaging findings were distributed as follows: 92 (23%) segments were considered positive. Of those, 16 segments were radiologically graded as level of suspicion of 3/5, 41 with 4/5 and 35 were graded 5/5. Table 2 reports the detailed diagnostic properties of mpMRI in identifying any cancerous lesions in the anatomical zones -apex, base, anterior and posterior prostate (Fig. 1b) . Considering all prostate segments analyzed, mpMRI showed high NPV (84-100%) and specificity (79-85%) for Gleason ≥7 and for clinically significant cancer (Table 2) . Diagnostic properties improved using the definitions of significant cancer rather than any cancer as the end-point. There was no substantial difference between the diagnostic properties of mpMRI based on the anatomical sector, albeit the posterior prostate was characterized by the highest NPV values. Table 3 details the diagnostic properties of mpMRI while accounting for levels of suspicion in the detection of cancer in the segments analyzed using the four end-points: any cancer, Gleason ≥7, and 0.2 and 0.5 mL threshold for clinical significance. Sensitivity and positive predictive values remained moderate for all the permutations of mpMRI suspicion levels and reference test definitions. However, there were important differences in NPV and specificity considering different suspicion thresholds and using different endpoints (Table 3) . Increasing the threshold for definition of positive mpMRI from 3/5 to 4/5 resulted in only minor drops of sensitivity and virtually unchanged NPVs, but improved specificity and PPV by several percentage points, suggesting that equivocal mpMRI results (3/5) could be considered negative with no deleterious impact on the diagnostic properties of the study.
Furthermore, mpMRI highly suspicious for significant cancer (5/5) showed high specificity values ranging between 96% and 97% for all four considered end-points with PPV for any cancer approaching 80%. These values are also valid under the PI-RADS v.2 definition of clinically significant lesions (GS ≥7, 0.5 mL or larger and/or presence of extraprostatic extension) and may suggest that these lesions could represent potential high-yield targets for confirmatory imageguided biopsies.
Discussion
Multiparametric MRI is a potentially useful tool on the detection, localization and characterization of PCa in situ. In this study we evaluated the diagnostic properties of mpMRI (the index test) compared to 3-D TTMB histopathology (reference test) 19 in identifying any cancer, high-grade cancer and clinically significant cancer. The results suggest that mpMRI is characterized by high specificity and high negative predictive value. Specifically, for identifying clinically significant PCa, specificity and NPV approximated 90%. These data indicate that mpMRI can be an important stratification tool, whereby the information obtained can either guide a targeted biopsy or alter patient management altogether.
In the present study, we used TTMB histopathology as the reference standard. 19 TTMB allows for the most comprehensive sampling of the prostate in situ, thus avoiding the sampling bias associated with routine office based biopsies. On the other hand, two-thirds of the patients in this study did not have a diagnosis of cancer prior to mpMRI and TTMB and this allows for minimization of verification bias inherent to cohorts of patients who undergo prostatectomy for a known cancer.
The findings of this study show that mpMRI can rule out high-grade and clinically significant cancer (according PI-RADS v.2: GS ≥7, 0.5 mL or larger and/or presence of extraprostatic extension) with a good degree of certainty, with NPVs ranging in the 90% territory, based on the end-point considered. These findings are in line with previous reports showing high NPV values for mpMRI. 3, 6, 8, [20] [21] [22] [23] [24] [25] [26] [27] [28] [29] The differences in the NPV and specificity values are likely due to different cohort characteristics. While in most other studies, the patients had PCa diagnosed before mpMRI and had a prostatectomy specimen for pathological analyses, whereas two-thirds of our cohort had no prior diagnosis of cancer and the reference test was a biopsy whereby just 29% of segments harbored cancer. 3, 6, 21, 24, 25 Consistently high NPV across the available studies show that mpMRI can reliably exclude the presence of clinically significant disease with a 5-10% chance risk of missing significant PCa. The present findings are in agreement with the report by Abd-Alazeez et al. who analyzed the diagnostic properties of mpMRI in men with a prior negative TRUS biopsy. 29 Despite differences in analytic techniques used in their study, the findings remain similar to the present, with high NPV of mpMRI for clinically significant cancer. Furthermore, the findings of the present study suggest no clinically significant detriment to omitting biopsy of Likert scale 3 lesions given virtually unchanged NPVs and improved specificity. This appears to contrast with findings of mpMRI-fusion biopsy cohorts whereby PI-RADS v.2 three lesions were found to harbor Gleason 7 cancer in up to 10% of cases. 30, 31 We are, however, unsure of how these data compare with the present study, given the potential for targeting bias.
In the present study, PPV and sensitivity values were suboptimal for the accurate detection of clinically significant disease. However, high suspicion on mpMRI (5/5) had PPVs of 60-77% suggesting that these should represent targets for magnetic resonance-guided biopsies. Indeed, the specificity values for highly suspicious lesions (5/5) were in the high 96-97% range.
The results of the current study suggest the utility of mpMRI in several settings. First, in the setting of active surveillance, the ability of mpMRI to accurately rule out the presence of clinically significant disease might aid in appropriate candidate selection and reduce the chance of reclassification. Furthermore, in the setting of focal therapy, mpMRI could suggest the anatomical regions of the prostate that could be spared during focal treatment. Given high NPV, mpMRI negative sectors could be essentially considered negative for clinically significant disease and spared during treatment. Finally, not only could mpMRI guide targeted biopsies and thus potentially avoid random sampling and associated morbidity as well as overdiagnosis of potentially indolent lesions, but also one could hypothesize that mpMRI in select cases could obviate the need for prostate biopsy in the presence of negative imaging results. 32 These and other potential uses for mpMRI should be thoroughly investigated in further studies.
The present study's results should be interpreted with its limitations in mind. Its retrospective nature harbors inherent biases. Another potential pitfall is that the surgeon carrying out TTMB was not blinded to the mpMRI results, and a degree of mental fusion might have resulted in better sampling of regions deemed suspicious on MRI. We believe that the potential for this bias is minimized by systematic sampling through a grid rather than attempted targeted biopsy; in fact, as sampling is equal and thorough in all regions of the prostate, no targeted biopsy samples were taken in these men. Furthermore, in the present study, one radiologist interpreted the imaging results, and interobserver agreement remains an obstacle to interpretation of prostate mpMRI. 20 Finally, although we used TTMB histopathology as the reference test, its sampling nature might introduce biases, albeit this biopsy technique represents the most thorough prostate sampling and avoids certification biases associated with using radical prostatectomy specimens.
In the present study, the diagnostic properties of mpMRI showed high NPVs and specificity, suggesting this imaging modality could reliably rule out clinically significant cancer in targeted regions of the prostate. Furthermore, foci with high suspicion on mpMRI (5/5) are characterized by very high specificity for cancer-harboring lesions (96-97%) and moderate PPV (60-79%), and could represent targets for image-guided confirmatory biopsy. mpMRI is a useful tool for the minimally-invasive detection, localization and characterization of PCa, and represents a valuable addition to the diagnostic and management pathways for men who have or are suspected to have PCa.
